Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

More articles from Oncology, Basic Science Track

  • You have access
    Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-DFO-trastuzumab PET/CT
    Gary Ulaner, David Hyman, Dara Ross, Adriana Corben, Sarat Chandarlapaty, Shari Goldfarb, Mcarthur Heather, Joseph Erinjeri, Stephen Solomon, Hartmuth Kolb, Serge Lyashchenko, Jason Lewis and Jorge Carrasquillo
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 586;
  • You have access
    First-in-human studies characterizing a poly(ADP-ribose)polymerase (PARP) targeted tracer, 18F-FluorThanatrace (18F-FTT) for cancer imaging
    Delphine Chen, Samantha Dyroff, Loren Michel, Andrea Wang-Gillam, Benjamin Tan, Sharon Phillips, Christopher Bognar, Wenhua Chu, Dong Zhou, Robert Mach, Frank Brooks and Richard Laforest
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 582;
  • You have access
    IL13RA2 targeted alpha particle therapy against glioblastoma
    Anirudh Sattiraju, Darpan Pandya, Kiran Solingapuram Sai, Thaddeus Wadas, Denise Herpai, Waldemar Debinski and Akiva Mintz
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 634;
  • You have access
    [68Ga]NeoBomb1, a new potent GRPR-antagonist for PET imaging - Preclinical and first clinical evaluation in prostate cancer
    Berthold Nock, Aikaterini Kaloudi, Emmanouil Lymperis, Athina Giarika, Hendrik Bergsma, Dirk Mueller, Eric Krenning, Marion de Jong, Theodosia Maina and Richard Baum
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 583;
  • You have access
    First-in-human study of the 11β-hydroxysteroid dehydrogenase type 1 PET tracer [11C]AS2471907
    Yiyun Huang, Beata Planet, Nabeel Nabulsi, Shannan Henry, Ming-Qiang Zheng, Shu-fei Lin, David Matuskey, Mark Walzer, Gerard Marek and Richard Carson
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 580;
  • You have access
    Early detection of erlotinib treatment response in NSCLC xenograft tumors using hyperpolarized [1-13C]pyruvate MRS: comparison with FLT- and FDG-PET.
    Andreas Clemmensen, Abubakr El-Tahir, Carsten Nielsen, Lotte Kristensen, Jan Henrik Ardenkjær-Larsen and Andreas Kjaer
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 417;
  • You have access
    Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model
    Yasuhiro Ohshima, Shigeki Watanabe, Atsushi Tsuji, Kotaro Nagatsu, Tetsuya Sakashita, Akira Sugiyama, Yoshinobu Harada, Atsuo Waki, Keiichiro Yoshinaga and Noriko Ishioka
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 468;
  • You have access
    Effects of 68Ga-DOTATOC specific activity on somatostatin receptor quantitation
    Pedram Heidari, Francis Deng, Shadi Esfahani, Benjamin Larimer and Umar Mahmood
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 360;
  • You have access
    Use of paired FDG and 18F-Fluoride PET to predict response to therapy in patients with bone dominant metastases from breast cancer
    Lanell Peterson, Alena Novakova, Janet O'Sullivan, Finbarr O'Sullivan, Andrew Shields, Susan Montgomery, Hannah Linden, Julie Gralow, Georgianna Ellis, VK Gadi, William Barlow, Robert Doot, Erin Schubert, Lisa Dunnwald, Lawrence MacDonald, Paul Kinahan, David Mankoff and Jennifer Specht
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 415;
  • You have access
    Successful implementation of near-real-time central review of FDG PET/CT examinations for differentiating responders from non-responders in a Phase II multi-center combined modality therapy adaptive clinical trial
    Nathan Hall, Jun Zhang, David Poon and Michael Knopp
    Journal of Nuclear Medicine May 1, 2016, 57 (supplement 2) 359;

Pages

  • Previous
  • Next
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 50
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire